Last reviewed · How we verify

Anti-PDL-1 antibody

Bristol-Myers Squibb · Phase 1 active Biologic

Anti-PDL-1 antibody is a Biologic drug developed by Bristol-Myers Squibb. It is currently in Phase 1 development. Also known as: BMS-936559, MDX 1105.

At a glance

Generic nameAnti-PDL-1 antibody
Also known asBMS-936559, MDX 1105
SponsorBristol-Myers Squibb
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Anti-PDL-1 antibody

What is Anti-PDL-1 antibody?

Anti-PDL-1 antibody is a Biologic drug developed by Bristol-Myers Squibb.

Who makes Anti-PDL-1 antibody?

Anti-PDL-1 antibody is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).

Is Anti-PDL-1 antibody also known as anything else?

Anti-PDL-1 antibody is also known as BMS-936559, MDX 1105.

What development phase is Anti-PDL-1 antibody in?

Anti-PDL-1 antibody is in Phase 1.

Related